

Currently released so far... 12553 / 251,287
Browse latest releases
2010/12/01
2010/12/02
2010/12/03
2010/12/04
2010/12/05
2010/12/06
2010/12/07
2010/12/08
2010/12/09
2010/12/10
2010/12/11
2010/12/12
2010/12/13
2010/12/14
2010/12/15
2010/12/16
2010/12/17
2010/12/18
2010/12/19
2010/12/20
2010/12/21
2010/12/22
2010/12/23
2010/12/24
2010/12/25
2010/12/26
2010/12/27
2010/12/28
2010/12/29
2010/12/30
2011/01/01
2011/01/02
2011/01/04
2011/01/05
2011/01/07
2011/01/09
2011/01/10
2011/01/11
2011/01/12
2011/01/13
2011/01/14
2011/01/15
2011/01/16
2011/01/17
2011/01/18
2011/01/19
2011/01/20
2011/01/21
2011/01/22
2011/01/23
2011/01/24
2011/01/25
2011/01/26
2011/01/27
2011/01/28
2011/01/29
2011/01/30
2011/01/31
2011/02/01
2011/02/02
2011/02/03
2011/02/04
2011/02/05
2011/02/06
2011/02/07
2011/02/08
2011/02/09
2011/02/10
2011/02/11
2011/02/12
2011/02/13
2011/02/14
2011/02/15
2011/02/16
2011/02/17
2011/02/18
2011/02/19
2011/02/20
2011/02/21
2011/02/22
2011/02/23
2011/02/24
2011/02/25
2011/02/26
2011/02/27
2011/02/28
2011/03/01
2011/03/02
2011/03/03
2011/03/04
2011/03/05
2011/03/06
2011/03/07
2011/03/08
2011/03/09
2011/03/10
2011/03/11
2011/03/13
2011/03/14
2011/03/15
2011/03/16
2011/03/17
2011/03/18
2011/03/19
2011/03/20
2011/03/21
2011/03/22
2011/03/23
2011/03/24
2011/03/25
2011/03/26
2011/03/27
2011/03/28
2011/03/29
2011/03/30
2011/03/31
2011/04/01
2011/04/02
2011/04/03
2011/04/04
2011/04/05
2011/04/06
2011/04/07
2011/04/08
2011/04/09
2011/04/10
2011/04/11
2011/04/12
2011/04/13
2011/04/14
2011/04/15
2011/04/16
2011/04/17
2011/04/18
2011/04/19
2011/04/20
2011/04/21
2011/04/22
2011/04/23
2011/04/24
2011/04/25
2011/04/26
2011/04/27
2011/04/28
2011/04/29
2011/04/30
2011/05/01
2011/05/02
2011/05/03
2011/05/04
2011/05/05
2011/05/06
2011/05/07
2011/05/08
2011/05/09
2011/05/10
2011/05/11
2011/05/12
Browse by creation date
Browse by origin
Embassy Athens
Embassy Asuncion
Embassy Astana
Embassy Asmara
Embassy Ashgabat
Embassy Apia
Embassy Ankara
Embassy Amman
Embassy Algiers
Embassy Addis Ababa
Embassy Accra
Embassy Abuja
Embassy Abu Dhabi
Embassy Abidjan
Consulate Auckland
Consulate Amsterdam
Consulate Adana
American Institute Taiwan, Taipei
Embassy Bujumbura
Embassy Buenos Aires
Embassy Budapest
Embassy Bucharest
Embassy Brussels
Embassy Bridgetown
Embassy Bratislava
Embassy Brasilia
Embassy Bogota
Embassy Bishkek
Embassy Bern
Embassy Berlin
Embassy Belmopan
Embassy Belgrade
Embassy Beirut
Embassy Beijing
Embassy Banjul
Embassy Bangkok
Embassy Bandar Seri Begawan
Embassy Bamako
Embassy Baku
Embassy Baghdad
Consulate Barcelona
Embassy Copenhagen
Embassy Conakry
Embassy Colombo
Embassy Chisinau
Embassy Caracas
Embassy Canberra
Embassy Cairo
Consulate Curacao
Consulate Ciudad Juarez
Consulate Chennai
Consulate Casablanca
Consulate Cape Town
Consulate Calgary
Embassy Dushanbe
Embassy Dublin
Embassy Doha
Embassy Djibouti
Embassy Dili
Embassy Dhaka
Embassy Dar Es Salaam
Embassy Damascus
Embassy Dakar
Consulate Dubai
Embassy Helsinki
Embassy Harare
Embassy Hanoi
Consulate Ho Chi Minh City
Consulate Hermosillo
Consulate Hamilton
Consulate Hamburg
Consulate Halifax
Embassy Kyiv
Embassy Kuwait
Embassy Kuala Lumpur
Embassy Kinshasa
Embassy Kingston
Embassy Kigali
Embassy Khartoum
Embassy Kathmandu
Embassy Kampala
Embassy Kabul
Consulate Kolkata
Embassy Luxembourg
Embassy Luanda
Embassy London
Embassy Ljubljana
Embassy Lisbon
Embassy Lima
Embassy Lilongwe
Embassy La Paz
Consulate Lahore
Consulate Lagos
Mission USOSCE
Mission USNATO
Mission UNESCO
Embassy Muscat
Embassy Moscow
Embassy Montevideo
Embassy Monrovia
Embassy Minsk
Embassy Mexico
Embassy Mbabane
Embassy Maputo
Embassy Manila
Embassy Manama
Embassy Managua
Embassy Malabo
Embassy Madrid
Consulate Munich
Consulate Mumbai
Consulate Montreal
Consulate Monterrey
Consulate Milan
Consulate Melbourne
Embassy Nicosia
Embassy Niamey
Embassy New Delhi
Embassy Ndjamena
Embassy Nassau
Embassy Nairobi
Consulate Naples
Consulate Naha
Embassy Pristina
Embassy Pretoria
Embassy Prague
Embassy Port Of Spain
Embassy Port Louis
Embassy Port Au Prince
Embassy Phnom Penh
Embassy Paris
Embassy Paramaribo
Embassy Panama
Consulate Peshawar
REO Basrah
Embassy Rome
Embassy Riyadh
Embassy Riga
Embassy Reykjavik
Embassy Rangoon
Embassy Rabat
Consulate Rio De Janeiro
Consulate Recife
Secretary of State
Embassy Suva
Embassy Stockholm
Embassy Sofia
Embassy Skopje
Embassy Singapore
Embassy Seoul
Embassy Sarajevo
Embassy Santo Domingo
Embassy Santiago
Embassy Sanaa
Embassy San Salvador
Embassy San Jose
Consulate Strasbourg
Consulate St Petersburg
Consulate Shenyang
Consulate Shanghai
Consulate Sapporo
Consulate Sao Paulo
Embassy Tunis
Embassy Tripoli
Embassy Tokyo
Embassy The Hague
Embassy Tel Aviv
Embassy Tehran
Embassy Tegucigalpa
Embassy Tbilisi
Embassy Tashkent
Embassy Tallinn
Consulate Toronto
Consulate Tijuana
USUN New York
USEU Brussels
US Office Almaty
US Mission Geneva
US Interests Section Havana
US Delegation, Secretary
UNVIE
Embassy Ulaanbaatar
Embassy Vilnius
Embassy Vienna
Embassy Vatican
Embassy Valletta
Consulate Vladivostok
Consulate Vancouver
Browse by tag
APECO
ASEC
AMGT
AFIN
APER
ACABQ
AORC
AEMR
AF
AE
AR
AGMT
AU
AY
ABLD
AS
AG
AJ
APCS
AX
AM
AMEX
ATRN
ADM
AMED
AFGHANISTAN
AZ
AL
ASUP
AND
ARM
ASEAN
AFFAIRS
AQ
ATFN
AMBASSADOR
AODE
APEC
ACBAQ
AFSI
AFSN
AO
ABUD
AC
ADPM
ADCO
ASIG
ARF
AUC
ASEX
AGAO
AA
AER
AVERY
AGRICULTURE
AIT
AADP
ASCH
AORL
AROC
ACOA
ANET
AID
AMCHAMS
AINF
AMG
AFU
AN
ALOW
ASECKFRDCVISKIRFPHUMSMIGEG
ACS
ADANA
AECL
ACAO
AORG
AGR
BEXP
BR
BM
BG
BL
BA
BTIO
BO
BP
BC
BILAT
BK
BU
BD
BRUSSELS
BB
BF
BBSR
BIDEN
BX
BE
BH
BT
BY
BMGT
BWC
BTIU
BN
CA
CASC
CFED
CO
CH
CS
CU
CE
CI
CM
CMGT
CJAN
COM
CG
CIS
CVIS
CR
CKGR
CHR
CVR
COUNTER
CIA
CLINTON
CY
CPAS
CD
CBW
COUNTERTERRORISM
CITEL
CDG
CW
CODEL
COUNTRY
CLEARANCE
COE
CN
CARICOM
CB
CONDOLEEZZA
CWC
CACS
CSW
CIDA
CIC
CITT
CONS
CL
CACM
CDB
CDC
CAN
CF
CJUS
CTM
CBSA
CARSON
CT
CLMT
CBC
CEUDA
CV
COPUOS
CTR
CROS
CAPC
CAC
CNARC
CICTE
CBE
ECON
ETRD
EIND
ENRG
EC
ELAB
EAGR
EAID
EFIS
EFIN
EINV
EUN
EG
EPET
EAIR
EU
ELTN
EWWT
ECIN
ERD
EI
ETTC
EUR
EN
EZ
ETC
ENVI
EMIN
ET
ENVR
ER
ECPS
EINT
EAP
ES
ENIV
ECONOMY
EXTERNAL
EINN
EFTA
ECONOMIC
EPA
EXBS
ECA
ELN
ETRDEINVECINPGOVCS
ENGR
ECUN
ENGY
ECONOMICS
ELECTIONS
EIAR
EINDETRD
EREL
EUC
ECONEFIN
EURN
EDU
ETRDEINVTINTCS
ECIP
ENERG
EFIM
EAIDS
EK
ETRDECONWTOCS
EINVETC
ECONCS
EUNCH
ESA
ECINECONCS
EUREM
ESENV
EFINECONCS
ETRC
ENNP
EAIG
EXIM
EEPET
EINVECONSENVCSJA
EUMEM
ETRA
ERNG
ETRO
ETRN
EINVEFIN
ICTY
IN
IS
IR
IC
IZ
IA
INTERPOL
IAEA
IT
IMO
IO
IV
ID
IRAQI
IEA
INRB
IL
IWC
ITU
ICAO
ISRAELI
ICRC
IIP
IMF
IBRD
ISLAMISTS
ITALY
ITALIAN
ILO
IPR
IQ
IRS
IAHRC
IZPREL
IRAJ
IDP
ILC
ITF
ICJ
IF
ITPHUM
INMARSAT
ISRAEL
IACI
IBET
ITRA
INR
IRC
IDA
ICTR
IGAD
INRA
INRO
IEFIN
INTELSAT
INTERNAL
INDO
ITPGOV
KWMN
KSCA
KDEM
KTFN
KIPR
KCRM
KPAL
KE
KPAO
KPKO
KS
KN
KISL
KFRD
KJUS
KIRF
KFLO
KG
KTIP
KTER
KRCM
KTIA
KGHG
KIRC
KU
KPRP
KMCA
KMPI
KSEO
KNNP
KZ
KNEI
KCOR
KOMC
KCFC
KSTC
KMDR
KFLU
KSAF
KSEP
KSAC
KR
KGIC
KSUM
KWBG
KCIP
KDRG
KOLY
KAWC
KCHG
KHDP
KRVC
KBIO
KAWK
KGCC
KHLS
KBCT
KPLS
KREL
KCFE
KMFO
KV
KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG
KFTFN
KVPR
KTDB
KSPR
KIDE
KVRP
KTEX
KBTR
KTRD
KICC
KCOM
KO
KLIG
KDEMAF
KMRS
KRAD
KOCI
KSTH
KUNR
KNSD
KGIT
KFSC
KHIV
KPAI
KICA
KACT
KHUM
KREC
KSEC
KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG
KCMR
KPIN
KESS
KDEV
KNAR
KNUC
KPWR
KENV
KWWMN
KWMNCS
KPRV
KOM
KBTS
KCRS
KNPP
KWNM
KRFD
KVIR
KTBT
KAID
KRIM
KDDG
KRGY
KHSA
KWMM
KMOC
KSCI
KPAK
KX
KPAONZ
KCGC
KID
KPOA
KIFR
KFIN
KWAC
KOMS
KCRCM
KNUP
KMIG
KNNPMNUC
KERG
KTLA
KCSY
KJUST
MOPS
MARR
MASS
MNUC
MX
MCAP
MO
MR
MI
MD
MK
MA
MP
MY
MTCRE
MOPPS
MASC
MIL
MTS
MLS
MILI
MAR
MU
MEPN
MAPP
MTCR
MEPI
MZ
MEETINGS
MG
MW
MAS
MT
MCC
MIK
ML
MARAD
MV
MERCOSUR
MTRE
MPOS
MEPP
MILITARY
MDC
MQADHAFI
MUCN
MRCRE
MAPS
MEDIA
MASSMNUC
MC
NZ
NZUS
NL
NU
NATO
NP
NO
NIPP
NE
NH
NR
NA
NPT
NI
NSF
NG
NSG
NAFTA
NC
NDP
NEW
NRR
NATIONAL
NT
NS
NASA
NAR
NV
NORAD
NSSP
NK
NPA
NGO
NSC
NATOPREL
NW
NPG
NSFO
OPDC
OTRA
OIIP
OREP
OVIP
OSCE
OEXC
OIE
OPRC
OAS
OPIC
OTR
OMIG
OSAC
OFFICIALS
OECD
OSCI
OBSP
OFDA
OPCW
ODIP
OFDP
OES
OPAD
OCII
OHUM
OVP
ON
OIC
OCS
PHUM
PREL
PGOV
PINR
PTER
PARM
PREF
PM
PE
PINS
PK
PHSA
PBTS
PRGOV
PA
PORG
PP
PS
PGOF
PL
PO
PARMS
PKFK
PSOE
PEPR
PAK
POL
PPA
PINT
PMAR
PRELP
PREFA
PALESTINIAN
PBIO
PINF
PNG
PMIL
PFOR
PUNE
PGOVLO
PAO
POLITICS
PHUMBA
PSEPC
PTBS
PCUL
PROP
PNAT
PNR
POLINT
PGOVE
PROG
PHALANAGE
PARTY
PDEM
PECON
PROV
PHUMPREL
PGOC
PY
PCI
PLN
PDOV
PREO
PGIV
PHUH
PAS
PU
POGOV
PF
PINL
POV
PAHO
PRL
PG
PRAM
POLITICAL
PARTIES
POLICY
PGOVSMIGKCRMKWMNPHUMCVISKFRDCA
PGGV
PHUS
PSA
PHUMPGOV
PEL
PSI
PAIGH
POSTS
PBT
PTERE
RS
RU
RW
RM
RO
RP
REGION
RSP
RF
RICE
RCMP
RFE
RIGHTS
RIGHTSPOLMIL
ROBERT
RUPREL
RELATIONS
ROOD
REACTION
RSO
REPORT
SENV
SNAR
SCUL
SR
SC
SOCI
SMIG
SI
SP
SU
SO
SW
SY
SA
SZ
SAN
SF
SN
STEINBERG
SG
ST
SIPDIS
SNARIZ
SNARN
SSA
SK
SPCVIS
SOFA
SAARC
SL
SEVN
SARS
SIPRS
SHUM
SANC
SWE
SHI
SYR
SNARCS
SPCE
SYRIA
SEN
SH
SCRS
SENVKGHG
TRGY
TSPL
TPHY
TSPA
TBIO
TI
TW
THPY
TX
TU
TS
TZ
TC
TH
TT
TIP
TO
TERRORISM
TRSY
TINT
TN
TURKEY
TBID
TL
TV
TNGD
TD
TF
TP
TFIN
TAGS
TK
TR
UNSC
UK
UNGA
UN
US
UNHRC
UG
UP
UNMIK
UNHCR
UE
USTR
UNVIE
UAE
UZ
UY
UNO
UNESCO
USEU
USOAS
UV
UNODC
UNCHS
UNFICYP
UNEP
UNIDROIT
UNDESCO
UNDP
UNPUOS
UNC
UNAUS
USUN
UNCHC
UNCHR
UNCND
UNICEF
UNCSD
UNDC
USNC
USPS
USAID
Browse by classification
Community resources
courage is contagious
Viewing cable 06WELLINGTON40, DRUG INDUSTRY SEES POSSIBLE SALVE TO ITS PAIN IN
If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:
- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06WELLINGTON40.
Reference ID | Created | Released | Classification | Origin |
---|---|---|---|---|
06WELLINGTON40 | 2006-01-13 05:15 | 2011-04-28 00:00 | CONFIDENTIAL//NOFORN | Embassy Wellington |
VZCZCXYZ0000
RR RUEHWEB
DE RUEHWL #0040/01 0130515
ZNY CCCCC ZZH
R 130515Z JAN 06
FM AMEMBASSY WELLINGTON
TO RUEHC/SECSTATE WASHDC 2273
INFO RUEHBY/AMEMBASSY CANBERRA 4273
RUEHDN/AMCONSUL SYDNEY 0417
RUCPDOC/USDOC WASHDC 0022
C O N F I D E N T I A L WELLINGTON 000040
SIPDIS
SENSITIVE
SIPDIS
DEPARTMENT FOR EAP/ANP-DRICCI AND EB/TPP/BTA/ANA-MBGOODMAN
STATE PASS TO USTR FOR BWEISEL
COMMERCE FOR 4530/ITA/MAC/AP/OSAO/ABENAISSA
E.O. 12958: DECL: 01/12/2016
TAGS: ECON ETRD NZ
SUBJECT: DRUG INDUSTRY SEES POSSIBLE SALVE TO ITS PAIN IN
NEW ZEALAND
REF: A. 05 WELLINGTON 577
¶B. 05 WELLINGTON 119
¶C. 04 WELLINGTON 1037
(U) Classified by Charge d'Affaires David R. Burnett.
Reason: 1.4 (b) and (d).
Summary
-------
¶1. (SBU) The pharmaceutical industry in New Zealand is
enjoying a dose of optimism about the prospect of changes to
the government's drug-purchasing system, which has crimped
the industry for the past 12 years. The government has
promised a review of the system that controls the range and
price of most prescription medicines in New Zealand, at a
time when patient and doctors' attacks on its drug-purchasing
agency have escalated. Nonetheless, most drug companies
continue to believe that only the lure of a free-trade
agreement between New Zealand and the United States would
prompt the New Zealand government to make the changes the
industry contends are needed to assure its long-term
viability in the country.
Pressuring PHARMAC
------------------
¶2. (U) Since 1993, the Pharmaceutical Management Agency
(PHARMAC) has decided which medicines will be subsidized by
the government and how much reimbursement will be paid.
PHARMAC controls the purchase of about 80 percent of
prescription pharmaceuticals in New Zealand. The agency's
aim is to contain pharmaceutical spending, and it has largely
succeeded. While the total number of prescriptions written
for most drugs has risen since 1997, the average price of
prescriptions has decreased, mainly as a result of price
reductions negotiated by PHARMAC with drug manufacturers.
The focus on holding down costs has meant that many
cutting-edge drugs are not subsidized or that manufacturers
withhold certain unsubsidized drugs from the New Zealand
market because their negligible sales discourage efforts to
secure regulatory approval (ref C).
¶3. (U) Over the past year, PHARMAC has come under increased
political criticism, greater scrutiny by the media and
sharper questioning by the public. First, it mishandled the
supply of the nation's influenza vaccine before last winter's
flu season. To secure the best deal, PHARMAC placed its
entire vaccine order with Sanofi Pasteur, which then
encountered a manufacturing problem in late February 2005
that left New Zealand 150,000 doses short. Alternate
suppliers eventually were found, and PHARMAC now insists on
dual sources for vaccines. But the incident highlighted the
agency's common practice of maximizing discounts by
negotiating with a single supplier.
¶4. (U) Patient groups, doctors and the public have become
increasingly vocal about PHARMAC's shortcomings -- a contrast
from past years in which consumers generally believed that if
PHARMAC did not fund a drug, it was not worth having (ref C).
Uppermost in the public's mind is the agency's failure to
fund modern medicines for a range of illnesses including
early stage breast cancer, heart disease, HIV/AIDS and
Alzheimer's. PHARMAC last year backed down from several
decisions that sparked outrage among doctors and patients.
For instance, the agency had hoped to save NZ $1 million (US
$697,300) by halting subsidies for the asthma drug Ventolin
in favor of Salamol, a cheaper substitute. After a public
outcry, PHARMAC announced it would allow patients to choose
either product for a two-year period. In perhaps the most
significant expression of public unhappiness with PHARMAC, 25
non-government health organizations on November 24 launched
the Access to Medicines NGO Coalition, calling for a review
of PHARMAC.
¶5. (U) The past year also has seen a surge in newspaper
articles describing the plight of patients with
life-threatening diseases who were unable to afford
unsubsidized medicines. Professional criticism is also on
the rise. Several cancer specialists told reporters that New
Zealand lagged other Western countries in providing publicly
funded access to the latest cancer drugs. A cardiologist
said doctors increasingly were being forced to treat patients
with outmoded medications. The New Zealand Medical Journal
published a series of case studies criticizing PHARMAC's
practices, including its sole-supply agreements, the
asthma-drug decision and the failure to subsidize certain
medicines.
¶6. (C) These developments provide mounting evidence of eroded
public confidence in PHARMAC, according to Lesley Clarke,
chief executive officer of Researched Medicines Industry
Association of New Zealand (RMI), the industry's trade
association. She also noted that, after the flu-vaccine
debacle, then Minister of Health Annette King acknowledged
for the first time that PHARMAC needed improvement.
Reviewing Pharmac
-----------------
¶7. (U) The Labour government has promised to develop "a
long-term medicines strategy relating to quality
pharmaceutical usage in the health sector including the role
PHARMAC should play in implementing that strategy." Labour
made that commitment as part of its agreement with the United
Future party to form a government after the September 17
elections. The opposition National Party, which created
PHARMAC while in government in 1993, also supports an agency
review.
¶8. (SBU) PHARMAC says it welcomes such a review, which it
hopes will bring about an increase in the budget for drug
purchases. According to Stuart Bruce, the agency's
communications and external relations manager, PHARMAC last
year ordered a review of its decision-making process for
high-cost drugs and expects to consider proposed changes this
year. Bruce said PHARMAC has found it increasingly difficult
to choose between funding expensive drugs for less common
diseases and funding cheaper medicines that help larger
numbers of patients.
¶9. (C) A new health minister, Pete Hodgson, also may portend
a more hospitable environment for the pharmaceutical
industry. According to Clarke of RMI, Hodgson, a former
veterinarian and science teacher, acknowledges a link between
a strong biotechnology sector -- one of the government's top
economic goals -- and research and development funded by the
pharmaceutical industry. Faced with a restrictive business
environment, the industry over the last decade has slashed
its research spending in New Zealand. Hodgson's predecessor,
Annette King, took a different view of the pharmaceutical
industry, telling its representatives that if the industry
disappeared from New Zealand, the country would simply source
its medicines elsewhere.
Industry in flux
----------------
¶10. (C) These potential changes come at a moment when many of
the pharmaceutical firms are reporting that, for the first
time in years, they are not cutting staff. A couple company
chief executives also noted that, for the first time in three
to four years, they have succeeded in getting a new drug
funded -- albeit, at the cost of accepting further reductions
in the subsidized prices of other products. On the other
hand, GlaxoSmithKline (GSK) last year reduced its staff in
New Zealand by 73 percent, to fewer than 15 positions. It
lost to competitor companies in trying to win subsidies for
several of its leading drugs, and a couple of its competitors
say that GSK is paying a price for publicly and aggressively
challenging PHARMAC a couple years ago.
¶11. (C) Many of the pharmaceutical companies believe that
only a U.S. offer of free-trade negotiations would induce the
New Zealand government to consider significant policy changes
that would affect the industry's competitive position. One
company representative cited the government's suspension of a
study on extending the effective patent life for
pharmaceuticals as evidence of the government's decision to
forgo any changes to pharmaceutical policies that might be
used as trade-offs in negotiating a free-trade agreement
(FTA). The industry wants many of the same concessions that
were provided in the Australia-U.S. FTA, particularly
requiring greater transparency in the drug-purchasing
agency's decision-making and the right to appeal its
decisions. In addition, the industry wants a longer
effective patent life for pharmaceuticals and a change in
PHARMAC's reference-pricing practice, or subsidizing a
pharmaceutical at the level of the lowest-priced medicine in
a therapeutic subgroup. The industry wants a commitment to
greater funding of pharmaceutical purchases.
¶12. (C) Meanwhile, a local area working group (LAWG) was
formed last year by eight pharmaceutical companies that are
based in the United States or do business there. The group
includes two companies -- Pfizer and GSK -- that withdrew
from RMI over the past two years in disagreement over RMI's
priorities. The LAWG's professed aim is to work on issues
that might be raised in FTA negotiations and address concerns
beyond just pharmaceuticals, such as investment in research
and development. However, RMI -- which LAWG members said
would continue to serve as the industry's public spokesperson
-- worries that there may not be room for both groups. The
formation of another industry group may give the government
(and PHARMAC) more leverage in playing one company off
another. However, the LAWG's formation also may foreshadow a
more aggressive approach by the industry toward the
government.
Comment
-------
¶13. (C) Notwithstanding U.S. government views on a possible
FTA with New Zealand, post believes that the formation of a
new coalition government provides a timely opportunity to
foster dialogue between the pharmaceutical industry and the
government. Post is working with the British High Commission
to co-host informal meetings between the industry and
government that would aim to reduce the animosity that has
characterized their relations. (The British are assisting us
to prevent the appearance of a U.S.-only initiative.) This
ideally would allow each side to gain a better understanding
of each other and to recognize common goals. The intent is
to supplement the efforts of both RMI and the LAWG.
Burnett